Overview
In plain English
DSIP — Delta Sleep-Inducing Peptide — was isolated in the 1970s from the cerebral venous blood of rabbits during induced delta-wave sleep, and was found to induce the same EEG pattern when transferred to recipient animals.
It is studied in published research for sleep architecture and delta EEG activity, stress adaptation and hypothalamic–pituitary–adrenal signalling, and thermoregulation. No receptor for it has been identified. Strictly for laboratory research use. Not for human or veterinary consumption.
- What it isA nine-amino-acid peptide first isolated from the brain during delta sleep
- Mainly studied forSleep architecture, delta EEG activity, stress and HPA-axis signalling
- Supplied asLyophilised powder, 10mg vial, independently assayed
How it works
What it actually does
Honestly: the mechanism is unknown. That is the standing position in the published literature, not a hedge.
No receptor for DSIP has ever been identified, so there is no confirmed mechanism. Proposed contributions include modulation of GABAergic and glutamatergic tone and of hypothalamic–pituitary–adrenal output.
It also clears from circulation very quickly, yet central effects have been reported long after it is undetectable — which is exactly why reviewers have called it an unresolved riddle.
The science in detail
DSIP originates in one of the more unusual isolation experiments in neuropeptide research. Working in Basel in the 1970s, Monnier and Schoenenberger perfused the cerebral ventricular system of rabbits during electrically induced delta-wave sleep and recovered a dialysate fraction that induced delta EEG activity when transferred to recipient animals. The active material was characterised as a nonapeptide and synthesised; Schoenenberger et al. (Pflügers Archiv, 1977) reported the amino acid analysis, sequence and activity of the synthetic compound.
The molecule is small, uncharged at several positions and carries no disulphide bridge. It is reported to cross the blood-brain barrier, and its plasma half-life is short — a combination that has complicated interpretation of the experimental literature, since measurable central effects have been reported at time points well beyond the peptide's detectable presence in circulation.
No specific DSIP receptor has been cloned or characterised. This is the central unresolved problem in the field, and it is the reason Kovalzon and Strekalova titled their mini-review in the Journal of Neurochemistry (2006) "Delta sleep-inducing peptide (DSIP): a still unresolved riddle". Without an identified binding site, the mechanistic literature is necessarily descriptive. Proposed contributions include modulation of GABAergic and glutamatergic tone, interaction with opioid systems, and influence on hypothalamic–pituitary–adrenal axis output.
The functional literature is correspondingly mixed. Reported observations extend well beyond sleep — into thermoregulation, stress adaptation, and oxidative stress models — and several groups have failed to reproduce the original delta-wave findings. Bes et al. (Neuropsychobiology, 1992) reported a double-blind study of sleep efficiency and latency that found statistically significant but weak effects and no change in subjective sleep quality; the authors concluded the findings were of limited magnitude.
Mechanistically, DSIP is therefore unlike the GABA-A positive allosteric modulators that dominate hypnotic pharmacology. It is not a sedative in that sense, and the research interest lies in the endogenous regulatory system it may represent rather than in a defined receptor action.
Evidence
What the research shows
Discovered by transferring deep sleep
Fluid taken from rabbits in delta-wave sleep induced the same brain-wave pattern in recipient animals.
Sequence confirmed in 1977
The synthetic version was characterised and published as a nine-amino-acid peptide.
No receptor has ever been found
Fifty years on, the binding site and mechanism remain unidentified.
Human study results were weak
A double-blind study reported only weak effects on sleep measures — the literature is small and inconsistent.
Reconstitution & handling
Reconstitution and handling in the laboratory
These are general handling notes for the lyophilised peptide supplied by Purist Peptides. They describe the preparation of a stock solution for laboratory work. They are not a dosing protocol, and they describe no administration to a person or an animal.
A 3ml vial of bacteriostatic water is included free with every peptide vial you order, so the material can be reconstituted on arrival.
DSIP 10mg — preparing a stock solution
Choice of diluent
Bacteriostatic water (water for injection with 0.9% benzyl alcohol) is the usual diluent where a stock will be drawn from repeatedly, because the preservative permits several septum entries across a working period. Sterile water for injection and sterile 0.9% sodium chloride are both used where a single-use preparation is wanted instead. The diluent volume sets the concentration of the stock, so record it.
Sterile technique
- Allow the sealed vial to reach room temperature before opening the carton — reconstituting a cold lyophilised cake slows dissolution
- Work in a clean area or a laminar flow cabinet, and wipe the rubber septum with 70% isopropyl alcohol, letting it dry fully
- Draw the chosen volume of diluent using a sterile single-use syringe and needle
- Angle the needle so the diluent runs down the inside wall of the vial — do not direct the stream onto the lyophilised cake
- Roll the vial gently between the palms until the cake has dissolved completely. Do not shake and do not vortex: peptides are surface-active, and agitation drives foaming and aggregation
- Let the vial stand for 5 to 10 minutes. A correctly reconstituted solution is clear and free of visible particles
Working out the concentration
Concentration follows from the mass in the vial and the volume of diluent added, nothing else. Adding 2ml of diluent to the 10mg vial gives a 5mg/ml stock; adding 1ml gives 10mg/ml. Label every reconstituted vial with its concentration and the date it was prepared.
Storage and stability
Before reconstitution
The lyophilised powder is the stable form. Sealed vials are best held at −20°C, protected from light and from moisture; the short periods at 2 to 6°C that occur in transit and on arrival are expected and are accounted for in the supply chain. Keep the vial in its carton — light and humid air are the two ordinary causes of loss on storage.
After reconstitution
Hold reconstituted solution at 2 to 6°C and protect it from light. Do not freeze a working stock: freeze-thaw cycling is the main avoidable cause of degradation and of visible precipitate. Where material must be held beyond a short working period, aliquot the stock into sterile low-binding tubes and freeze the aliquots once at −20°C or below, thawing each aliquot only once.
Checks before use
Inspect every vial against a light source. Discard any solution that is hazy, discoloured or contains particles, and any vial whose septum integrity is in doubt. The independent HPLC assay report for the batch supplied is available on request.
Strictly for laboratory research use. Not for human or veterinary consumption.
Questions
Frequently asked questions
What is DSIP studied for?
Published work covers sleep architecture and delta EEG activity, thermoregulation, stress adaptation and hypothalamic–pituitary–adrenal signalling, and oxidative stress models. The literature is small, spread across four decades, and inconsistent in its findings. Purist supplies the compound for laboratory research only.
Does DSIP bind a known receptor?
No. No DSIP receptor has been cloned or characterised, and this remains the principal open question in the field — the basis for Kovalzon and Strekalova's 2006 Journal of Neurochemistry review describing the peptide as a still unresolved riddle.
Why is the DSIP sleep literature inconsistent?
Several groups have been unable to reproduce the original delta-wave findings, and reported central effects often outlast the peptide's measurable presence in circulation. Study designs, routes and assay methods also vary considerably across the four decades of published work.
How does DSIP differ from GABAergic hypnotics?
Benzodiazepines and Z-drugs are positive allosteric modulators at the GABA-A receptor, a defined and well-characterised target. DSIP has no identified receptor and is not a sedative in that pharmacological sense; research interest centres on the endogenous system it may represent.
How is purity verified?
Every batch is assayed by independent HPLC at Bioindustrial Services in Boksburg. We do not rely on the manufacturer's own certificate alone. The assay report for the batch you receive is available on request, and our full testing protocol is set out at Quality Standards.
How long does delivery take?
Orders are dispatched from South Africa, with timelines varying by region and courier. Current dispatch and transit windows are set out at Delivery Process.
What is the returns policy?
Unopened vials in original condition may be returned under the conditions set out at Refund Policy.
The Purist Research Standard
Precision-engineered peptides designed to maintain structural integrity under rigorous laboratory conditions.
Optimized Logistics & Fulfillment
Our logistics and fulfillment protocols are engineered to prioritize research stability.
≥99% Research-Grade Purity
Every compound is synthesized to exceed a 99% purity threshold.
Third-Party Laboratory Verified
We maintain total transparency through independent COA.
Precision Lyophilization Technology
Our advanced flash-freeze and vacuum-drying process.
Controlled Synthesis Environment
Produced in sterile, ISO-compliant facilities.
Targeted Research Utility
Engineered as reliable biological models.
Recommended Products
Essential Compounds for Precision Research: Top-Tier Peptides Verified for Structural Integrity.
Testimonials
Real feedback from customers who prioritize purity, precision, and uncompromising quality standards.
